CN
CN
CN

News 2022-08-23

Porton Reports Strong Interim Results 2022

The year 2022 is an important milestone for Porton. Despite of the uncertainties of the external environment, we always keep in mind Porton’s mission of "Enabling public’s early access to good medicines" to overcome those challenges and ensure delivery through an agile and stable management system. In the future, we will maintain keen insights and be more proactive in embracing changes so as to empower our business and help good medicines become accessible to the public earlier.

Become part of Porton's community to access personalized insights and resources.
Subscribe to the Newsletter
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.

This website contains product information intended for different regions and may include details that are not available or authorized in your country. Please be aware that we assume no responsibility for any access to such information that may contravene applicable laws, regulations, or usage restrictions in your jurisdiction.

Become part of Porton's community to access personalized insights and resources.
Submit
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.
US: (609) 860-1300
CN: (86) 23-8608-3200